Performance of individual items of the quantitative myasthenia gravis score

T Carolina Barnett1, Vera Bril, Aileen M Davis

  • 1Department of Medicine (Neurology), University of Toronto, Canada. c.barnetttapia@utoronto.ca

We evaluated the quantitative myasthenia gravis score to determine which items better discriminate among patients and are most responsive to treatment. Current scoring ranges were compared to updated normative data when appropriate. Data from a previous study of intravenous immunoglobulin versus placebo in myasthenia gravis were analyzed. Each item of the quantitative myasthenia gravis score was analyzed for distribution, responsiveness and inter-item correlations. Items on swallowing, speaking and vital capacity had marked floor effects as did grip strength based on current normative data. The timed measures were responsive to treatment but diplopia, vital capacity and grip strength were not. Ocular items were not correlated with bulbar and generalized items (p>0.05), suggesting multi-dimensionality. Contralateral arm and leg tests were highly correlated (r>0.9, p<0.001), indicating redundancy. In summary, we found that the bulbar items and grip strength did not perform well. Timed items from the Quantitative Myasthenia Gravis Score, representing fatigability, are responsive to change and we propose new ranges based on updated normative data.

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...